| 查看: 581 | 回复: 3 | |||
[交流]
求高人帮翻译一段说明书 急~
|
|||
|
1 General Responding patients may not experience an improvement in performance status on therapy and may experience worsening. The relationship between changes in performance status, response to therapy, and treatment-related side effects has not been established. 2 Cutaneous Localized erythema of the extremities with edema followed by desquamation has been observed. In case of severe skin toxicity, an adjustment in dosage is recommended [see Dose Adjustments During Treatment (2.7)]. The discontinuation rate due to skin toxicity was 1.6% (15/965) for metastatic breast cancer patients. Among 92 breast cancer patients premedicated with 3-day corticosteroids, there were no cases of severe skin toxicity reported and no patient discontinued TAXOTERE due to skin toxicity. 3 Fluid Retention Severe fluid retention has been reported following TAXOTERE therapy [see Boxed Warning, Premedication Regimen (2.6)]. Patients should be premedicated with oral corticosteroids prior to each TAXOTERE administration to reduce the incidence and severity of fluid retention [see Premedication Regimen (2.6)]. Patients with pre-existing effusions should be closely monitored from the first dose for the possible exacerbation of the effusions. When fluid retention occurs, peripheral edema usually starts in the lower extremities and may become generalized with a median weight gain of 2 kg. Among 92 breast cancer patients premedicated with 3-day corticosteroids, moderate fluid retention occurred in 27.2% and severe fluid retention in 6.5%. The median cumulative dose to onset of moderate or severe fluid retention was 819 mg/m2. 9.8% (9/92) of patients discontinued treatment due to fluid retention: 4 patients discontinued with severe fluid retention; the remaining 5 had mild or moderate fluid retention. The median cumulative dose to treatment discontinuation due to fluid retention was 1021 mg/m2. Fluid retention was completely, but sometimes slowly, reversible with a median of 16 weeks from the last infusion of TAXOTERE to resolution (range: 0 to 42+ weeks). Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). 4 Neurologic Severe neurosensory symptoms (paresthesia, dysesthesia, pain) were observed in 5.5% (53/965) of metastatic breast cancer patients, and resulted in treatment discontinuation in 6.1%. When these symptoms occur, dosage must be adjusted. If symptoms persist, treatment should be discontinued [see Dose Adjustments During Treatment (2.7)]. Patients who experienced neurotoxicity in clinical trials and for whom follow-up information on the complete resolution of the event was available had spontaneous reversal of symptoms with a median of 9 weeks from onset (range: 0 to 106 weeks). Severe peripheral motor neuropathy mainly manifested as distal extremity weakness occurred in 4.4% (42/965). 5 Asthenia Severe asthenia has been reported in 14.9% (144/965) of metastatic breast cancer patients but has led to treatment discontinuation in only 1.8%. Symptoms of fatigue and weakness may last a few days up to several weeks and may be associated with deterioration of performance status in patients with progressive disease. 6. ADVERSE REACTIONS Adverse reactions are described for TAXOTERE according to indication. 6.1 Clinical Trial Experience • Breast Cancer Monotherapy with TAXOTERE for locally advanced or metastatic breast cancer after failure of prior chemotherapy TAXOTERE 100 mg/m2: Adverse drug reactions occurring in at least 5% of patients are compared for three populations who received TAXOTERE administered at 100 mg/m2 as a 1-hour infusion every 3 weeks: 2045 patients with various tumor types and normal baseline liver function tests; the subset of 965 patients with locally advanced or metastatic breast cancer, both previously treated and untreated with chemotherapy, who had normal baseline liver function tests; and an additional 61 patients with various tumor types who had abnormal liver function tests at baseline. These reactions were described using COSTART terms and were considered possibly or probably related to TAXOTERE. At least 95% of these patients did not receive hematopoietic support. The safety profile is generally similar in patients receiving TAXOTERE for the treatment of breast cancer and in patients with other tumor types (See Table 4). |
回复此楼» 猜你喜欢
材料与化工300求调剂
已经有26人回复
-
考研二轮调剂
已经有6人回复
-
材料复试求调剂
已经有17人回复
-
085601初试330分找调剂
已经有9人回复
-
291 求调剂
已经有12人回复
-
化学工程与技术324调剂
已经有17人回复
-
0856专硕求调剂 希望是a区院校
已经有12人回复
-
求调剂
已经有6人回复
-
求调剂 材料与工程 324分 专硕
已经有4人回复
-
博士自荐
已经有6人回复
» 抢金币啦！回帖就可以得到:
-
想做生物创新药的有福啦—南昌大学生物医学创新研究院/药学院陈川课题组招收博士生
+1/186
-
招统计机器学习理论硕士及博士生｜南京大学人工智能学院
+1/88
-
江西师大化学工程学院调剂今晚0点开放！ 缺额100个，速冲！
+1/84
-
2026年盐城工学院化学工程与技术专业（学硕）招收08和0703方向考生
+1/41
-
齐齐哈尔大学材料科学与工程学科招硕士研究生调剂
+1/40
-
招07及08开头化学、材料、环境、食品、生物与医药等调剂生
+2/20
-
大连大学-贵州省煤炭洁净利用重点实验室联合培养研究生 化学5人+环境工程7人
+1/16
-
2026广东医科大学生物医学工程学硕、电子信息专硕接收调剂
+1/14
-
重庆科技大学新能源与电子信息材料团队招收化学、物理、材料类调剂生
+1/11
-
辽宁工业大学土木工程（081400）专业调剂有名额
+1/11
-
大湾区大学李红庚课题组招聘研究助理
+1/6
-
国家大人才课题组招收化学、材料化工类2026年调剂生
+1/5
-
河北大学招收生物与医药专业调剂考生
+1/5
-
湖北师范大学2026硕士调剂 物理 光学 电子 材料相关专业
+1/5
-
济南大学天然药物化学生物学省重点实验室招收生物学、制药工程学专硕调剂
+1/4
-
0854,0858调剂招生
+1/3
-
上海交通大学化学化工学院张智涛课题组诚聘博士后
+1/2
-
2026年鲁东大学水产专业考研调剂-滨海生态高等研究院
+1/1
-
刘强教授团队招0802机械工程学硕和0855机械工程专硕调剂啦
+1/1
-
武汉轻工大学化环学院张老师课题组招收学硕调剂生
+1/1
3楼2011-04-06 14:46:32
这么长 4楼2011-04-06 15:01:20
简单回复
Mally892楼
2011-04-01 16:57
回复
suibowen2010(金币+1, 翻译EPI+1): 嘿嘿 没有办法啊 任务...看的不是很到位 很多话不知道怎么说 所以才来这求助高人啊~ 2011-04-01 19:48:04
ringzhu(翻译EPI-1): 无效应助 2011-04-06 12:41:16
哇！ringzhu(翻译EPI-1): 无效应助 2011-04-06 12:41:16
